Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) has reported positive results from a study on MB204 in the Oprm1 mouse model of autism. The research, conducted by Drs. Julie Le Merrer and Jerome Becker, showed that a single oral dose of MB204 successfully reversed social behavior deficits typically seen in the model within one hour of administration.
Key findings include:
- A high dose (2.5 mg/kg) of MB204 significantly restored social behavior in all measured endpoints (p<0.0001)
- A lower dose (1 mg/kg) also reversed nearly all social behavior deficits
- The higher dose even outperformed normal (non-autistic) mice on several endpoints
The researchers noted that MB204 showed more improvement and a hyper-social effect compared to previously tested drugs. Marvel is now testing MB204 in other autism spectrum disorder models, including Rett syndrome (Mecp2) and Fragile X syndrome (Fmr1).
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ha riportato risultati positivi da uno studio su MB204 nel modello murino di autismo Oprm1. La ricerca, condotta dai Dr. Julie Le Merrer e Jerome Becker, ha mostrato che una singola dose orale di MB204 ha invertito con successo i deficit comportamentali sociali tipicamente osservati nel modello entro un'ora dalla somministrazione.
I risultati chiave includono:
- Una dose elevata (2.5 mg/kg) di MB204 ha ripristinato significativamente il comportamento sociale in tutti i parametri misurati (p<0.0001)
- Una dose più bassa (1 mg/kg) ha anche invertito quasi tutti i deficit comportamentali sociali
- La dose più alta ha addirittura superato i topi normali (non autistici) in diversi parametri
I ricercatori hanno osservato che MB204 ha mostrato maggiori miglioramenti e un effetto iper-sociale rispetto ai farmaci testati in precedenza. Marvel sta ora testando MB204 in altri modelli di disturbo dello spettro autistico, inclusi la sindrome di Rett (Mecp2) e la sindrome dell'X fragile (Fmr1).
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ha reportado resultados positivos de un estudio sobre MB204 en el modelo de ratón Oprm1 para el autismo. La investigación, realizada por los Drs. Julie Le Merrer y Jerome Becker, demostró que una dosis oral única de MB204 revertió con éxito los déficits en el comportamiento social que se observan típicamente en el modelo en menos de una hora tras la administración.
Los hallazgos clave incluyen:
- Una dosis alta (2.5 mg/kg) de MB204 restauró significativamente el comportamiento social en todos los puntos medidos (p<0.0001)
- Una dosis más baja (1 mg/kg) también revirtió casi todos los déficits en el comportamiento social
- La dosis más alta incluso superó a los ratones normales (no autistas) en varios puntos de medición
Los investigadores señalaron que MB204 mostró más mejoría y un efecto hiper-social en comparación con los medicamentos testados anteriormente. Marvel está probando ahora MB204 en otros modelos de trastornos del espectro autista, incluidos el síndrome de Rett (Mecp2) y el síndrome del X frágil (Fmr1).
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF)은 Oprm1 마우스 자폐 모델에서 MB204에 대한 연구의 긍정적인 결과를 보고했습니다. Julie Le Merrer 박사와 Jerome Becker 박사가 수행한 연구에 따르면 MB204의 단일 경구 투여가 투여 후 1시간 이내에 모델에서 일반적으로 나타나는 사회적 행동 결핍을 성공적으로 역전시켰습니다.
주요 발견 사항은 다음과 같습니다:
- MB204의 고용량 (2.5 mg/kg)은 모든 측정된 지표에서 사회적 행동을 상당히 회복시켰습니다 (p<0.0001)
- 낮은 용량 (1 mg/kg)도 거의 모든 사회적 행동 결핍을 역전시켰습니다
- 고용량은 여러 지표에서 정상(비자폐증) 쥐보다도 성능이 우수했습니다
연구자들은 MB204가 이전에 테스트된 약물보다 더 많은 개선과 과도한 사회적 효과를 나타냈다고 언급했습니다. Marvel은 이제 Rett 증후군(Mecp2) 및 취약 X 증후군(Fmr1)을 포함한 다른 자폐 스펙트럼 장애 모델에서 MB204를 테스트하고 있습니다.
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) a rapporté des résultats positifs d'une étude sur MB204 dans le modèle murin Oprm1 de l'autisme. La recherche, menée par Dr Julie Le Merrer et Jerome Becker, a montré qu'une dose orale unique de MB204 a réussi à inverser les déficits de comportement social typiquement observés dans le modèle en moins d'une heure suivant l'administration.
Les résultats clés incluent :
- Une forte dose (2.5 mg/kg) de MB204 a significativement restauré le comportement social sur tous les points mesurés (p<0.0001)
- Une dose plus faible (1 mg/kg) a également inversé presque tous les déficits de comportement social
- La dose plus élevée a même surpassé les souris normales (non-autistes) sur plusieurs points
Les chercheurs ont noté que MB204 a montré une plus grande amélioration et un effet hyper-social par rapport aux médicaments testés auparavant. Marvel teste maintenant MB204 dans d'autres modèles de troubles du spectre autistique, y compris le syndrome de Rett (Mecp2) et le syndrome de l'X fragile (Fmr1).
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) hat positive Ergebnisse aus einer Studie zu MB204 im Oprm1 Mausmodell für Autismus berichtet. Die Forschung, die von Dr. Julie Le Merrer und Jerome Becker durchgeführt wurde, zeigte, dass eine einmalige orale Dosis von MB204 erfolgreich soziale Verhaltensdefizite im Modell innerhalb einer Stunde nach der Verabreichung umkehrte.
Wesentliche Ergebnisse umfassen:
- Eine hohe Dosis (2.5 mg/kg) von MB204 stellte das soziale Verhalten in allen gemessenen Endpunkten signifikant wieder her (p<0.0001)
- Eine niedrigere Dosis (1 mg/kg) kehrte ebenfalls nahezu alle sozialen Verhaltensdefizite um
- Die höhere Dosis übertraf sogar normale (nicht-autistische) Mäuse in mehreren Endpunkten
Die Forscher stellten fest, dass MB204 im Vergleich zu zuvor getesteten Medikamenten bessere Verbesserungen und einen hyper-sozialen Effekt zeigte. Marvel testet jetzt MB204 auch in anderen Modellen von Autismus-Spektrum-Störungen, einschließlich Rett-Syndrom (Mecp2) und Fragiles X-Syndrom (Fmr1).
- MB204 successfully reversed social behavior deficits in the Oprm1 mouse model of autism
- High dose (2.5 mg/kg) of MB204 significantly restored social behavior in all measured endpoints (p<0.0001)
- Lower dose (1 mg/kg) of MB204 also reversed nearly all social behavior deficits
- MB204 outperformed normal (non-autistic) mice on several endpoints, demonstrating a potent pro-social effect
- MB204 showed more improvement and a hyper-social effect compared to previously tested drugs like Istradefylline
- None.
Calgary, Alberta--(Newsfile Corp. - October 10, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study social behavior deficits). Marvel is pleased to report that just one hour after administering a single oral dose of MB204, the drug successfully reversed the social behaviour deficits typically seen in the model.
Key Highlights:
- A high dose of MB204 (2.5 mg/kg) significantly restored social behaviour in all measured endpoints (p<0.0001). Improvements were seen in social interaction behaviours including, the number and duration of nose contacts, the number and duration of paw contacts, and time spent self-grooming, amongst others.
- A lower dose of MB204 (1 mg/kg) also reversed nearly all social behaviour deficits, showing a clear connection between dose and response.
- The higher dose of MB204 not only improved/restored social interactions in Oprm1 (autistic) mice, but even outperformed the social interactions of normal (non-autistic) mice on several endpoints, demonstrating MB204's potent pro-social effect.
"These results are very encouraging," said Drs. Le Merrer and Becker, "MB204, at both doses, nearly reversed all the social deficits/endpoints in our autism model, and in some cases, the Oprm1 animals appeared to be more sociable than normal animals. We have previously tested Istradefylline (an off-patent approved drug similar to MB204), in multiple models of autism such as Oprm1, Mecp2, and Fmr1 but we have not seen this level of improvement or the hyper-social effect before."
Currently, Drs. Le Merrer and Becker are now testing MB204 in another chronic Rett syndrome model (Mecp2) and are looking forward to seeing how it performs 'head-to-head' against the approved drug Trofinetide.
"We are very pleased with these findings for MB204 and intend to publish them in a peer reviewed journal," said Marvel's Chief Science Officer, Dr. Mark Williams. "MB204 is currently being tested in two very clinically relevant autism spectrum disorder models of Rett syndrome (Mecp2) and Fragile X syndrome (Fmr1), the latter is in collaboration with the Fraxa Research Foundation, and we look forward to reviewing the results."
About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.
Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
Contact Information
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
All information contained in this news release with respect to the Company and its subsidiary, (collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226201
FAQ
What are the key results of Marvel Biosciences' MB204 study in the Oprm1 model of autism?
How does MB204 compare to other drugs tested in autism models by the researchers?
What are the next steps for Marvel Biosciences (MBCOF) in testing MB204 for autism spectrum disorders?
When did Marvel Biosciences (MBCOF) announce the results of the MB204 study in the Oprm1 model of autism?
